Targeted Alpha Therapy Using Components of the Plasminogen Activation System for the Control of Micrometastatic Breast Cancer

Abstract

Targeted alpha therapy (TAT) offers the potential to inhibit the growth of micrometastases by selectively killing isolated and preangiogenic clusters of cancer cells. The alpha emitting radioisotopes Tb-149 and Bi-213 were produced by accelerator and generator, respectively, and chelated to cancer affined monoclonal antibody, peptide or protein to form the alpha-immunoconjugates (AIC) and alpha-plasminogen activation inhibitor type-2 (API) against melanoma, leukaemia, breast, prostate and colorectal cancers. These conjugates are tested for stability, specificity and cytotoxicity, and found to be highly specific and cytotoxic in vitro. Subcutaneous inoculation of one million melanoma or breast cancer cells into the flanks or mammary pads, respectively, of nude mice causes tumours to grow in all mice. Melanoma and breast cancer tumour growth is obtained for untreated controls, nonspecific and specific TAT, for 2 days post-inoculation subcutaneous injection models. Only for TAT mice is complete inhibition of melanoma growth found.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Aug 01, 2000
Accession Number
ADB262232

Entities

People

  • Barry Allen

Tags

DTIC Thesaurus Topics

  • Amines
  • Amino Acids
  • Anhydrides
  • Biomedical Research
  • Body Weight
  • Breast Cancer
  • Cells
  • Chemistry
  • Colon Cancer
  • Confocal Microscopy
  • Health Services
  • Lymphatic System
  • Neoplasms
  • Oncology
  • Rodents

Fields of Study

  • Biology

Readers

  • Molecular Genetics
  • Oncology (Cancer Research).